Bronnendatabase

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)" arm (n=12 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Vomiting occurred in 3 participants (14.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Vomiting occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Vomiting occurred in 1 participants (14.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)" arm (n=41 at risk), Vomiting occurred in 5 participants (12.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)" arm (n=21 at risk), Vomiting occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)" arm (n=21 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)" arm (n=45 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)" arm (n=46 at risk), Vomiting occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)" arm (n=46 at risk), Vomiting occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)" arm (n=49 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)" arm (n=49 at risk), Vomiting occurred in 2 participants (4.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Vomiting occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)" arm (n=50 at risk), Vomiting occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Vomiting

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)" arm (n=52 at risk), Vomiting occurred in 2 participants (3.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)" arm (n=12 at risk), Gastrooesophageal reflux disease occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)" arm (n=12 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)" arm (n=41 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)" arm (n=21 at risk), Gastrooesophageal reflux disease occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)" arm (n=21 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)" arm (n=45 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)" arm (n=46 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)" arm (n=46 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)" arm (n=49 at risk), Gastrooesophageal reflux disease occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)" arm (n=49 at risk), Gastrooesophageal reflux disease occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Gastrooesophageal reflux disease occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)" arm (n=50 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Gastrooesophageal reflux disease

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)" arm (n=52 at risk), Gastrooesophageal reflux disease occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)" arm (n=12 at risk), Diarrhoea occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)" arm (n=12 at risk), Diarrhoea occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)" arm (n=41 at risk), Diarrhoea occurred in 1 participants (2.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)" arm (n=21 at risk), Diarrhoea occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)" arm (n=21 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)" arm (n=45 at risk), Diarrhoea occurred in 2 participants (4.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)" arm (n=46 at risk), Diarrhoea occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)" arm (n=46 at risk), Diarrhoea occurred in 3 participants (6.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)" arm (n=49 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)" arm (n=49 at risk), Diarrhoea occurred in 3 participants (6.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)" arm (n=50 at risk), Diarrhoea occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Diarrhoea

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)" arm (n=52 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 36 mg LY3502970 EPB Capsule (Fasted State)" arm (n=12 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 36 mg LY3502970 DF Capsule (Fasted State)" arm (n=12 at risk), Constipation occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 60 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Constipation occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 45 mg LY3502970 Tablet (Fasted State)" arm (n=21 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 13 (Day 85-91): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part B: Period 12 (Day 78-84): 35 mg LY3502970 Tablet (Fasted State)" arm (n=7 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 11 (Day 71-77): 37.5 mg LY3502970 Tablet (Fasted State)" arm (n=41 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 37.5 mg LY3502970 Tablet (Fed State)" arm (n=21 at risk), Constipation occurred in 2 participants (9.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 10 (Day 64-70): 36 mg LY3502970 Capsule (Fed State)" arm (n=21 at risk), Constipation occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 9 (Day 57-63): 36 mg LY3502970 Capsule (Fasted State)" arm (n=45 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 8 (Day 50-56): 20 mg LY3502970 Tablet (Fasted State)" arm (n=46 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 7 (Day 43-49): 16 mg LY3502970 Capsule (Fasted State)" arm (n=46 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 6 (Day 36-42): 10 mg LY3502970 Tablet (Fasted State)" arm (n=49 at risk), Constipation occurred in 6 participants (12.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 5 (Day 29-35): 8 mg LY3502970 Capsule (Fasted State)" arm (n=49 at risk), Constipation occurred in 2 participants (4.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 4 (Day 22-28): 5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Constipation occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 3 (Day 15-21): 2.5 mg LY3502970 Tablet (Fasted State)" arm (n=50 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 2 (Day 8-14): 2 mg LY3502970 Capsule (Fasted State)" arm (n=50 at risk), Constipation occurred in 5 participants (10.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Multiple Dose Study of LY3502970 in Healthy Overweight and — Constipation

Posted trial results for A Multiple Dose Study of LY3502970 in Healthy Overweight and Obese Participants (NCT05841238, PHASE1). In the "Part A: Period 1 (Day 1-7): 0.8 mg LY3502970 Tablet (Fasted State)" arm (n=52 at risk), Constipation occurred in 2 participants (3.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Headache

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Headache occurred in 6 participants (4.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Headache

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Headache occurred in 8 participants (5.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Decreased appetite occurred in 7 participants (4.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Decreased appetite

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Decreased appetite occurred in 12 participants (8.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Fatigue

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Fatigue occurred in 4 participants (2.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Fatigue

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Fatigue occurred in 8 participants (5.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Vomiting occurred in 14 participants (9.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Vomiting

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Vomiting occurred in 9 participants (6.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Gastrooesophageal reflux disease

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Gastrooesophageal reflux disease occurred in 8 participants (5.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Gastrooesophageal reflux disease

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Gastrooesophageal reflux disease occurred in 2 participants (1.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "4.5 mg Dulaglutide or MTD" arm (n=143 at risk), Constipation occurred in 11 participants (7.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of Tirzepatide (LY3298176) in Adult Participants Wit — Constipation

Posted trial results for A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) (NCT05564039, PHASE4). In the "15 mg Tirzepatide or MTD" arm (n=139 at risk), Constipation occurred in 12 participants (8.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Decreased appetite

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Decreased appetite

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Decreased appetite occurred in 4 participants (5.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Dizziness

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Dizziness

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Dizziness occurred in 6 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Alopecia

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Alopecia occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Alopecia

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Alopecia occurred in 7 participants (9.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Headache

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Headache occurred in 1 participants (10.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Headache

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Headache occurred in 17 participants (23.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Abdominal pain

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Abdominal pain occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Abdominal pain

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Abdominal pain occurred in 23 participants (31.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Fatigue

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Continued Medication (Semaglutide) (Weeks 60-72)" arm (n=10 at risk), Fatigue occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Semaglutide Treatment, Appetite, and Eating Behavior: Long-t — Fatigue

Posted trial results for Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects (NCT05548647, PHASE4). In the "Behavioral Treatment + Medication (Weeks 0-60)" arm (n=72 at risk), Fatigue occurred in 23 participants (31.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Vomiting

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (NCT05132088, PHASE3). In the "Oral Semaglutide 50 mg" arm (n=134 at risk), Vomiting occurred in 20 participants (14.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Gastrooesophageal reflux disease

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (NCT05132088, PHASE3). In the "Oral Semaglutide 50 mg" arm (n=134 at risk), Gastrooesophageal reflux disease occurred in 7 participants (5.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Dizziness

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (NCT05132088, PHASE3). In the "Oral Semaglutide 50 mg" arm (n=134 at risk), Dizziness occurred in 8 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Diarrhoea

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (NCT05132088, PHASE3). In the "Oral Semaglutide 50 mg" arm (n=134 at risk), Diarrhoea occurred in 22 participants (16.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — Research Study to Investigate How Well Semaglutide Tablets T — Decreased appetite

Posted trial results for Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (NCT05132088, PHASE3). In the "Oral Semaglutide 50 mg" arm (n=134 at risk), Decreased appetite occurred in 7 participants (5.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B" arm (n=18 at risk), Headache occurred in 2 participants (11.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2/3/6/8/12/24 mg LY3502970 QD - Part B" arm (n=17 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2(or 3)/3/6/12 mg LY3502970 QD - Part B" arm (n=14 at risk), Headache occurred in 3 participants (21.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "3 mg LY3502970 - Part A" arm (n=9 at risk), Headache occurred in 1 participants (11.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Headache

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2 mg LY3502970 - Part A" arm (n=10 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2(or 3)/3/6/12/24/36/45 mg LY3502970 QD - Part B" arm (n=18 at risk), Dizziness occurred in 1 participants (5.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2/3/6/8/12/24 mg LY3502970 QD - Part B" arm (n=17 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2(or 3)/3/6/12 mg LY3502970 QD - Part B" arm (n=14 at risk), Dizziness occurred in 1 participants (7.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "3 mg LY3502970 - Part A" arm (n=9 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Japanese Participants With Type 2 Di — Dizziness

Posted trial results for A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus (NCT05086445, PHASE1). In the "2 mg LY3502970 - Part A" arm (n=10 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide — Dizziness

Posted trial results for A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (NCT04596631, PHASE3). In the "Oral Semaglutide" arm (n=66 at risk), Dizziness occurred in 4 participants (6.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide — Decreased appetite

Posted trial results for A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (NCT04596631, PHASE3). In the "Oral Semaglutide" arm (n=66 at risk), Decreased appetite occurred in 2 participants (3.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Research Study to Compare a New Medicine Oral Semaglutide — Abdominal pain

Posted trial results for A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes (NCT04596631, PHASE3). In the "Oral Semaglutide" arm (n=66 at risk), Abdominal pain occurred in 6 participants (9.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 2 QD" arm (n=10 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 1 QD" arm (n=9 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 QD" arm (n=19 at risk), Headache occurred in 1 participants (5.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 12 mg LY3502970 QD" arm (n=19 at risk), Headache occurred in 2 participants (10.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 5 mg LY3502970 QD" arm (n=20 at risk), Headache occurred in 1 participants (5.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 2 mg LY3502970 QD" arm (n=21 at risk), Headache occurred in 1 participants (4.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part D: 3 mg LY3502970 Prototype Formulation" arm (n=6 at risk), Headache occurred in 1 participants (16.7%). Source: ClinicalTrials.gov results section, adverse events module.

LiveNOW from FOX — Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clini

Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX Source: LiveNOW from FOX Published: Thu, 21 May 2026 07:00:00 GMT Eli Lilly logo (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Retatrutide, Eli Lilly’s next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Lilly announced the clini

LiveNOW from FOX — Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clini

Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX Source: LiveNOW from FOX Published: Thu, 21 May 2026 07:00:00 GMT Eli Lilly logo (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Retatrutide, Eli Lilly’s next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Lilly announced the clini

LiveNOW from FOX — Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clini

Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX Source: LiveNOW from FOX Published: Thu, 21 May 2026 07:00:00 GMT Eli Lilly logo (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Retatrutide, Eli Lilly’s next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Lilly announced the clini

LiveNOW from FOX — Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clini

Retatrutide, Eli Lilly's next obesity drug, fueled dramatic weight loss in clinical trial - LiveNOW from FOX Source: LiveNOW from FOX Published: Thu, 21 May 2026 07:00:00 GMT Eli Lilly logo (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Retatrutide, Eli Lilly’s next generation of weight loss injections, showed dramatic results in clinical trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Lilly announced the clini

pharmaceutical-journal.com — Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journa

Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journal.com Source: pharmaceutical-journal.com Published: Fri, 22 May 2026 07:00:00 GMT Ekkawit Sansra/ Alamy Stock Photo All doses of obesity drug retatrutide resulted in clinically meaningful weight loss, while people with severe obesity on the highest dose lost up to 30% of their body weight over two years, topline results of a phase III clinical trial have shown. In an announcement published on 21 May 2026, Eli Lil

pharmaceutical-journal.com — Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journa

Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journal.com Source: pharmaceutical-journal.com Published: Fri, 22 May 2026 07:00:00 GMT Ekkawit Sansra/ Alamy Stock Photo All doses of obesity drug retatrutide resulted in clinically meaningful weight loss, while people with severe obesity on the highest dose lost up to 30% of their body weight over two years, topline results of a phase III clinical trial have shown. In an announcement published on 21 May 2026, Eli Lil

pharmaceutical-journal.com — Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journa

Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journal.com Source: pharmaceutical-journal.com Published: Fri, 22 May 2026 07:00:00 GMT Ekkawit Sansra/ Alamy Stock Photo All doses of obesity drug retatrutide resulted in clinically meaningful weight loss, while people with severe obesity on the highest dose lost up to 30% of their body weight over two years, topline results of a phase III clinical trial have shown. In an announcement published on 21 May 2026, Eli Lil

pharmaceutical-journal.com — Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journa

Phase III retatrutide study demonstrates 30% weight loss - pharmaceutical-journal.com Source: pharmaceutical-journal.com Published: Fri, 22 May 2026 07:00:00 GMT Ekkawit Sansra/ Alamy Stock Photo All doses of obesity drug retatrutide resulted in clinically meaningful weight loss, while people with severe obesity on the highest dose lost up to 30% of their body weight over two years, topline results of a phase III clinical trial have shown. In an announcement published on 21 May 2026, Eli Lil

PubMed — Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase

METHODS: Cohort D was a double-blind, placebo-controlled, phase 2b study in adults with T2D and MASH with fibrosis (F1-F3) on stable GLP-1RA therapy randomized (2:1) to receive efruxifermin 50 mg or placebo, once weekly for 12 weeks. The primary endpoint was safety and tolerability of efruxifermin added to a stable dose of GLP-1RA. Secondary endpoints included changes in hepatic fat fraction (HFF), markers of liver injury and fibrosis, and metabolic parameters. RESULTS: Adults (N = 31) with

PubMed — Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.

AIMS: Tirzepatide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity across Phase 3 clinical trials. MATERIALS AND METHODS: This post hoc analysis evaluated results from the SURMOUNT-1 through -5 (including SURMOUNT-1

PubMed — Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.

AIMS: Tirzepatide is a once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) approved for weight management in adults with obesity. Data on older adults remain limited, however. This study aimed to examine tirzepatide's safety and efficacy in adults aged ≥ 65 years with obesity across Phase 3 clinical trials. MATERIALS AND METHODS: This post hoc analysis evaluated results from the SURMOUNT-1 through -5 (including SURMOUNT-1

Google News (X/Twitter search) — Common GLP-1 side effects include nausea and diarrhea, but hospitalization is ra

Tweet/X post: Common GLP-1 side effects include nausea and diarrhea, but hospitalization is rare. An @EndoHopkins case report examines an adverse gastrointestinal event caused by temporary GLP-1 discontinuation for fasting during Ramadan. @CureusMedical @zilb - x.com Published: Fri, 11 Sep 2026 14:15:00 GMT Common GLP-1 side effects include nausea and diarrhea, but hospitalization is rare. An @EndoHopkins case report examines an adverse gastrointestinal event caused by temporary GLP-1 disconti

Google News (X/Twitter search) — Common GLP-1 side effects include nausea and diarrhea, but hospitalization is ra

Tweet/X post: Common GLP-1 side effects include nausea and diarrhea, but hospitalization is rare. An @EndoHopkins case report examines an adverse gastrointestinal event caused by temporary GLP-1 discontinuation for fasting during Ramadan. @CureusMedical @zilb - x.com Published: Fri, 11 Sep 2026 14:15:00 GMT Common GLP-1 side effects include nausea and diarrhea, but hospitalization is rare. An @EndoHopkins case report examines an adverse gastrointestinal event caused by temporary GLP-1 disconti

Google News (X/Twitter search) — There's a clear takeaway from this study. Consider thiamine supplementation when

Tweet/X post: There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/oBQGNNde0m - x.com Published: Thu, 10 Sep 2026 12:02:17 GMT There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/

Google News (X/Twitter search) — There's a clear takeaway from this study. Consider thiamine supplementation when

Tweet/X post: There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/oBQGNNde0m - x.com Published: Thu, 10 Sep 2026 12:02:17 GMT There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/

Google News (X/Twitter search) — There's a clear takeaway from this study. Consider thiamine supplementation when

Tweet/X post: There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/oBQGNNde0m - x.com Published: Thu, 10 Sep 2026 12:02:17 GMT There's a clear takeaway from this study. Consider thiamine supplementation when you see these side effects on GLP1 RAs: ▪ Persistent nausea, vomiting, low food intake, rapid weight loss Here's why: https://t.co/

BBC (MHRA-safety search) — Two deaths reported to drug watchdog over potential link to weight-loss jabs - B

Two deaths reported to drug watchdog over potential link to weight-loss jabs - BBC Source: BBC Published: Mon, 09 Mar 2026 07:00:00 GMT The deaths of two people in Northern Ireland potentially linked to weight-loss injections have been reported to the government agency responsible for ensuring medicines are safe. The two cases are among more than 500 suspected adverse drug reaction reports submitted from Northern Ireland over the last two years related to GLP-1 medications. The drugs, prescr

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fed" arm (n=12 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fasted" arm (n=12 at risk), Headache occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 24 mg LY3502970 QD" arm (n=17 at risk), Headache occurred in 5 participants (29.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 16 mg LY3502970 QD" arm (n=8 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 12 mg LY3502970 QD" arm (n=17 at risk), Headache occurred in 4 participants (23.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 8 mg LY3502970 QD" arm (n=9 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 6 mg LY3502970 QD" arm (n=8 at risk), Headache occurred in 3 participants (37.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 5 mg LY3502970 QD" arm (n=17 at risk), Headache occurred in 1 participants (5.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 4 mg LY3502970 QD" arm (n=18 at risk), Headache occurred in 4 participants (22.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 2 mg LY3502970 QD" arm (n=45 at risk), Headache occurred in 3 participants (6.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 6 mg LY3502970" arm (n=6 at risk), Headache occurred in 2 participants (33.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 3 mg LY3502970" arm (n=6 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 1 mg LY3502970" arm (n=6 at risk), Headache occurred in 1 participants (16.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Headache

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 0.3 mg LY3502970" arm (n=6 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 2 QD" arm (n=10 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 1 QD" arm (n=9 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 QD" arm (n=19 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 12 mg LY3502970 QD" arm (n=19 at risk), Dizziness occurred in 1 participants (5.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 5 mg LY3502970 QD" arm (n=20 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 2 mg LY3502970 QD" arm (n=21 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part D: 3 mg LY3502970 Prototype Formulation" arm (n=6 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fed" arm (n=12 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fasted" arm (n=12 at risk), Dizziness occurred in 1 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 24 mg LY3502970 QD" arm (n=17 at risk), Dizziness occurred in 1 participants (5.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 16 mg LY3502970 QD" arm (n=8 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 12 mg LY3502970 QD" arm (n=17 at risk), Dizziness occurred in 1 participants (5.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 8 mg LY3502970 QD" arm (n=9 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 6 mg LY3502970 QD" arm (n=8 at risk), Dizziness occurred in 1 participants (12.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 5 mg LY3502970 QD" arm (n=17 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 4 mg LY3502970 QD" arm (n=18 at risk), Dizziness occurred in 2 participants (11.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 2 mg LY3502970 QD" arm (n=45 at risk), Dizziness occurred in 3 participants (6.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 6 mg LY3502970" arm (n=6 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 3 mg LY3502970" arm (n=6 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 1 mg LY3502970" arm (n=6 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Dizziness

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 0.3 mg LY3502970" arm (n=6 at risk), Dizziness occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 2 QD" arm (n=10 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 1 QD" arm (n=9 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 QD" arm (n=19 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 12 mg LY3502970 QD" arm (n=19 at risk), Decreased appetite occurred in 2 participants (10.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 5 mg LY3502970 QD" arm (n=20 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 2 mg LY3502970 QD" arm (n=21 at risk), Decreased appetite occurred in 2 participants (9.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part D: 3 mg LY3502970 Prototype Formulation" arm (n=6 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fed" arm (n=12 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fasted" arm (n=12 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 24 mg LY3502970 QD" arm (n=17 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 16 mg LY3502970 QD" arm (n=8 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 12 mg LY3502970 QD" arm (n=17 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 8 mg LY3502970 QD" arm (n=9 at risk), Decreased appetite occurred in 1 participants (11.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 6 mg LY3502970 QD" arm (n=8 at risk), Decreased appetite occurred in 1 participants (12.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 5 mg LY3502970 QD" arm (n=17 at risk), Decreased appetite occurred in 1 participants (5.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 4 mg LY3502970 QD" arm (n=18 at risk), Decreased appetite occurred in 1 participants (5.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 2 mg LY3502970 QD" arm (n=45 at risk), Decreased appetite occurred in 4 participants (8.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 6 mg LY3502970" arm (n=6 at risk), Decreased appetite occurred in 1 participants (16.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 3 mg LY3502970" arm (n=6 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 1 mg LY3502970" arm (n=6 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Decreased appetite

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 0.3 mg LY3502970" arm (n=6 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 2 QD" arm (n=10 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 1 QD" arm (n=9 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 QD" arm (n=19 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 12 mg LY3502970 QD" arm (n=19 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 5 mg LY3502970 QD" arm (n=20 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 2 mg LY3502970 QD" arm (n=21 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part D: 3 mg LY3502970 Prototype Formulation" arm (n=6 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fed" arm (n=12 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fasted" arm (n=12 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 24 mg LY3502970 QD" arm (n=17 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 16 mg LY3502970 QD" arm (n=8 at risk), Diarrhoea occurred in 1 participants (12.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 12 mg LY3502970 QD" arm (n=17 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 8 mg LY3502970 QD" arm (n=9 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 6 mg LY3502970 QD" arm (n=8 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 5 mg LY3502970 QD" arm (n=17 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 4 mg LY3502970 QD" arm (n=18 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 2 mg LY3502970 QD" arm (n=45 at risk), Diarrhoea occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 6 mg LY3502970" arm (n=6 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 3 mg LY3502970" arm (n=6 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 1 mg LY3502970" arm (n=6 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Diarrhoea

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 0.3 mg LY3502970" arm (n=6 at risk), Diarrhoea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 2 QD" arm (n=10 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 Formulation 1 QD" arm (n=9 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 24 mg LY3502970 QD" arm (n=19 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 12 mg LY3502970 QD" arm (n=19 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 5 mg LY3502970 QD" arm (n=20 at risk), Constipation occurred in 1 participants (5.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part E 2 mg LY3502970 QD" arm (n=21 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part D: 3 mg LY3502970 Prototype Formulation" arm (n=6 at risk), Constipation occurred in 1 participants (16.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fed" arm (n=12 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part C 3 mg LY3502970 Fasted" arm (n=12 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 24 mg LY3502970 QD" arm (n=17 at risk), Constipation occurred in 2 participants (11.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 16 mg LY3502970 QD" arm (n=8 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 12 mg LY3502970 QD" arm (n=17 at risk), Constipation occurred in 2 participants (11.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 8 mg LY3502970 QD" arm (n=9 at risk), Constipation occurred in 2 participants (22.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 6 mg LY3502970 QD" arm (n=8 at risk), Constipation occurred in 1 participants (12.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 5 mg LY3502970 QD" arm (n=17 at risk), Constipation occurred in 3 participants (17.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 4 mg LY3502970 QD" arm (n=18 at risk), Constipation occurred in 6 participants (33.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part B 2 mg LY3502970 QD" arm (n=45 at risk), Constipation occurred in 5 participants (11.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 6 mg LY3502970" arm (n=6 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 3 mg LY3502970" arm (n=6 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 1 mg LY3502970" arm (n=6 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study of LY3502970 in Healthy Participants — Constipation

Posted trial results for A Study of LY3502970 in Healthy Participants (NCT03929744, PHASE1). In the "Part A 0.3 mg LY3502970" arm (n=6 at risk), Constipation occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 17.2 mg LY3502970 Tablet QD" arm (n=176 at risk), Headache occurred in 6 participants (3.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 36 mg LY3502970 Capsule QD" arm (n=176 at risk), Headache occurred in 28 participants (15.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:14.5 mg LY3502970 Tablet QD" arm (n=180 at risk), Headache occurred in 15 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:24 mg LY3502970 Capsule QD" arm (n=181 at risk), Headache occurred in 18 participants (9.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:9 mg LY3502970 Tablet QD" arm (n=186 at risk), Headache occurred in 18 participants (9.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing)" arm (n=213 at risk), Headache occurred in 23 participants (10.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B:5.5 mg LY3502970 Tablet QD" arm (n=203 at risk), Headache occurred in 17 participants (8.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 6 mg LY3502970 Capsule QD" arm (n=203 at risk), Headache occurred in 25 participants (12.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 2.5 mg LY3502970 Tablet QD" arm (n=210 at risk), Headache occurred in 17 participants (8.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 3 mg LY3502970 Capsule QD" arm (n=210 at risk), Headache occurred in 37 participants (17.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 0.8 mg LY3502970 Tablet QD" arm (n=213 at risk), Headache occurred in 19 participants (8.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 1 mg LY3502970 Capsule QD" arm (n=215 at risk), Headache occurred in 34 participants (15.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 18)" arm (n=45 at risk), Headache occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 17)" arm (n=45 at risk), Headache occurred in 3 participants (6.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 16)" arm (n=45 at risk), Headache occurred in 2 participants (4.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 36 mg LY3502970 Capsule QD" arm (n=45 at risk), Headache occurred in 3 participants (6.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 15)" arm (n=50 at risk), Headache occurred in 2 participants (4.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 14)" arm (n=49 at risk), Headache occurred in 3 participants (6.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 13)" arm (n=49 at risk), Headache occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 24 mg LY3502970 Capsule QD" arm (n=50 at risk), Headache occurred in 5 participants (10.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 12)" arm (n=50 at risk), Headache occurred in 3 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Drug-Drug Interaction (DDI) Study of Orforglipron With Car — Fatigue

Posted trial results for A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants (NCT06370728, PHASE1). In the "Carbamazepine Alone (Days 6-18 Except Day 15, and Days 19-35)" arm (n=29 at risk), Fatigue occurred in 1 participants (3.4%). Source: ClinicalTrials.gov results section, adverse events module.

Penn Medicine — Diabetic GLP-1 use linked to increased hair loss risk - Penn Medicine

Diabetic GLP-1 use linked to increased hair loss risk - Penn Medicine Source: Penn Medicine Published: Mon, 31 Aug 2026 07:00:00 GMT Diabetic GLP-1 use linked to increased hair loss risk  Penn Medicine

The Guardian — From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weig

From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs - The Guardian Source: The Guardian Published: Fri, 11 Sep 2026 14:00:00 GMT Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false FALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress h

The Guardian — From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weig

From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs - The Guardian Source: The Guardian Published: Fri, 11 Sep 2026 14:00:00 GMT Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false FALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress h

The Guardian — From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weig

From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs - The Guardian Source: The Guardian Published: Fri, 11 Sep 2026 14:00:00 GMT Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false FALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress h

The Guardian — From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weig

From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs - The Guardian Source: The Guardian Published: Fri, 11 Sep 2026 14:00:00 GMT Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false FALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress h

The Guardian — From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weig

From ‘Ozempic breath’ to hair loss: sorting the science from the hype about weight loss jabs - The Guardian Source: The Guardian Published: Fri, 11 Sep 2026 14:00:00 GMT Do you gain weight once you stop using them? Do they make your face saggy? Can they improve your mental health? Experts explain whether 13 common beliefs about GLP-1s are true or false FALSE “GLP-1 medications mimic Glucagon-like peptide-1 – one of the hormones involved in appetite regulation. It doesn’t completely suppress h

thepharmacist.co.uk — Revealed: How ICBs are taking their own approaches to Mounjaro prescribing - the

Revealed: How ICBs are taking their own approaches to Mounjaro prescribing - thepharmacist.co.uk Source: thepharmacist.co.uk Published: Mon, 02 Mar 2026 08:00:00 GMT It was one of the biggest health stories of last year. In June 2025, GPs were given the go ahead to start prescribing tirzepatide (Mounjaro) for obesity. While it has been available since 2022 as a treatment for diabetes, this new indication arrived in a blaze of glory, making front pages, and being described as a ‘game changer’ i

thepharmacist.co.uk — Revealed: How ICBs are taking their own approaches to Mounjaro prescribing - the

Revealed: How ICBs are taking their own approaches to Mounjaro prescribing - thepharmacist.co.uk Source: thepharmacist.co.uk Published: Mon, 02 Mar 2026 08:00:00 GMT It was one of the biggest health stories of last year. In June 2025, GPs were given the go ahead to start prescribing tirzepatide (Mounjaro) for obesity. While it has been available since 2022 as a treatment for diabetes, this new indication arrived in a blaze of glory, making front pages, and being described as a ‘game changer’ i

BBC — Weight-loss jabs will be offered on NHS for people at risk of further heart atta

Weight-loss jabs will be offered on NHS for people at risk of further heart attacks - BBC Source: BBC Published: Wed, 01 Apr 2026 07:00:00 GMT Weight-loss jab Wegovy will be offered for free on the NHS to more than a million people in England at risk of heart attacks and strokes. The watchdog NICE, external says people with these health issues, or serious circulation problems in their legs, and who are overweight, should have the weekly jab "as an extra layer of protection". A GP or speciali

GOV.UK — First GLP-1 tablet for weight loss approved in the UK - GOV.UK

First GLP-1 tablet for weight loss approved in the UK - GOV.UK Source: GOV.UK Published: Thu, 11 Jun 2026 07:00:00 GMT Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. The UK’s first GLP-1 receptor agonist tablet for weight loss and weight management has today (11 June 2026) been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Alongside a reduced

GOV.UK — First GLP-1 tablet for weight loss approved in the UK - GOV.UK

First GLP-1 tablet for weight loss approved in the UK - GOV.UK Source: GOV.UK Published: Thu, 11 Jun 2026 07:00:00 GMT Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. The UK’s first GLP-1 receptor agonist tablet for weight loss and weight management has today (11 June 2026) been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Alongside a reduced

GOV.UK — First GLP-1 tablet for weight loss approved in the UK - GOV.UK

First GLP-1 tablet for weight loss approved in the UK - GOV.UK Source: GOV.UK Published: Thu, 11 Jun 2026 07:00:00 GMT Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. The UK’s first GLP-1 receptor agonist tablet for weight loss and weight management has today (11 June 2026) been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Alongside a reduced

GOV.UK — First GLP-1 tablet for weight loss approved in the UK - GOV.UK

First GLP-1 tablet for weight loss approved in the UK - GOV.UK Source: GOV.UK Published: Thu, 11 Jun 2026 07:00:00 GMT Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management. The UK’s first GLP-1 receptor agonist tablet for weight loss and weight management has today (11 June 2026) been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Alongside a reduced

PubMed — Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Revi

Pharmaceuticals (Basel). 2024 Jun 24;17(7):828. doi: 10.3390/ph17070828. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. Liu L(1), Shi H(2), Shi Y(3), Wang A(4), Guo N(5), Tao H(6), Nahata MC(1)(7). Author information: (1)Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. (2)Depart

PubMed — Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Revi

Pharmaceuticals (Basel). 2024 Jun 24;17(7):828. doi: 10.3390/ph17070828. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. Liu L(1), Shi H(2), Shi Y(3), Wang A(4), Guo N(5), Tao H(6), Nahata MC(1)(7). Author information: (1)Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. (2)Depart

PubMed — Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Revi

Pharmaceuticals (Basel). 2024 Jun 24;17(7):828. doi: 10.3390/ph17070828. Comparative Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity or Overweight: A Systematic Review and Network Meta-Analysis. Liu L(1), Shi H(2), Shi Y(3), Wang A(4), Guo N(5), Tao H(6), Nahata MC(1)(7). Author information: (1)Institute of Therapeutic Innovations and Outcomes (ITIO), College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA. (2)Depart

PubMed — Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and

J Endocrinol Invest. 2026 Aug 6. doi: 10.1007/s40618-026-03006-y. Online ahead of print. Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis. Pałka W(1), Moćko P(2), Śladowska K(3), Holko P(3), Kawalec P(4). Author information: (1)Faculty of Health Sciences, Institute of Public Health, Jagiellonian University Medical College, ul. Skawińska 8, 31-066, Krakow, Poland. (2)D

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 11)" arm (n=50 at risk), Headache occurred in 2 participants (4.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 10)" arm (n=50 at risk), Headache occurred in 3 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 12 mg LY3502970 Capsule QD" arm (n=50 at risk), Headache occurred in 2 participants (4.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)" arm (n=52 at risk), Headache occurred in 5 participants (9.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 9)" arm (n=46 at risk), Headache occurred in 3 participants (6.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 8)" arm (n=47 at risk), Headache occurred in 2 participants (4.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 7)" arm (n=46 at risk), Headache occurred in 2 participants (4.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 6 mg LY3502970 Capsule QD" arm (n=46 at risk), Headache occurred in 4 participants (8.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 6)" arm (n=51 at risk), Headache occurred in 2 participants (3.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 5)" arm (n=48 at risk), Headache occurred in 3 participants (6.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 4)" arm (n=51 at risk), Headache occurred in 2 participants (3.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 3 mg LY3502970 Capsule QD" arm (n=47 at risk), Headache occurred in 1 participants (2.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 3)" arm (n=52 at risk), Headache occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 2)" arm (n=52 at risk), Headache occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 1)" arm (n=52 at risk), Headache occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Headache

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 1 mg LY3502970 Capsule QD" arm (n=52 at risk), Headache occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 17.2 mg LY3502970 Tablet QD" arm (n=176 at risk), Decreased appetite occurred in 2 participants (1.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 36 mg LY3502970 Capsule QD" arm (n=176 at risk), Decreased appetite occurred in 1 participants (0.6%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:14.5 mg LY3502970 Tablet QD" arm (n=180 at risk), Decreased appetite occurred in 5 participants (2.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:24 mg LY3502970 Capsule QD" arm (n=181 at risk), Decreased appetite occurred in 4 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:9 mg LY3502970 Tablet QD" arm (n=186 at risk), Decreased appetite occurred in 5 participants (2.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:12 mg LY3502970 Capsule QD" arm (n=186 at risk), Decreased appetite occurred in 1 participants (0.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B:5.5 mg LY3502970 Tablet QD" arm (n=203 at risk), Decreased appetite occurred in 1 participants (0.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 6 mg LY3502970 Capsule QD" arm (n=203 at risk), Decreased appetite occurred in 3 participants (1.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 2.5 mg LY3502970 Tablet QD" arm (n=210 at risk), Decreased appetite occurred in 3 participants (1.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 3 mg LY3502970 Capsule QD" arm (n=210 at risk), Decreased appetite occurred in 15 participants (7.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 0.8 mg LY3502970 Tablet QD" arm (n=213 at risk), Decreased appetite occurred in 4 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 1 mg LY3502970 Capsule QD" arm (n=215 at risk), Decreased appetite occurred in 8 participants (3.7%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 18)" arm (n=45 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 17)" arm (n=45 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 16)" arm (n=45 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 36 mg LY3502970 Capsule QD" arm (n=45 at risk), Decreased appetite occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 15)" arm (n=50 at risk), Decreased appetite occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 14)" arm (n=49 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 13)" arm (n=49 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 24 mg LY3502970 Capsule QD" arm (n=50 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 12)" arm (n=50 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 11)" arm (n=50 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 10)" arm (n=50 at risk), Decreased appetite occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 12 mg LY3502970 Capsule QD" arm (n=50 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)" arm (n=52 at risk), Decreased appetite occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 9)" arm (n=46 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 8)" arm (n=47 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 7)" arm (n=46 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 6 mg LY3502970 Capsule QD" arm (n=46 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 6)" arm (n=51 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 5)" arm (n=48 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 4)" arm (n=51 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 3 mg LY3502970 Capsule QD" arm (n=47 at risk), Decreased appetite occurred in 1 participants (2.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 3)" arm (n=52 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 2)" arm (n=52 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 1)" arm (n=52 at risk), Decreased appetite occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Decreased appetite

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 1 mg LY3502970 Capsule QD" arm (n=52 at risk), Decreased appetite occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 17.2 mg LY3502970 Tablet QD" arm (n=176 at risk), Nausea occurred in 6 participants (3.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B: 36 mg LY3502970 Capsule QD" arm (n=176 at risk), Nausea occurred in 9 participants (5.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:14.5 mg LY3502970 Tablet QD" arm (n=180 at risk), Nausea occurred in 15 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:24 mg LY3502970 Capsule QD" arm (n=181 at risk), Nausea occurred in 31 participants (17.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:9 mg LY3502970 Tablet QD" arm (n=186 at risk), Nausea occurred in 12 participants (6.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2B:12 mg LY3502970 Capsule QD" arm (n=186 at risk), Nausea occurred in 32 participants (17.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B:5.5 mg LY3502970 Tablet QD" arm (n=203 at risk), Nausea occurred in 17 participants (8.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 6 mg LY3502970 Capsule QD" arm (n=203 at risk), Nausea occurred in 19 participants (9.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 2.5 mg LY3502970 Tablet QD" arm (n=210 at risk), Nausea occurred in 13 participants (6.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 3 mg LY3502970 Capsule QD" arm (n=210 at risk), Nausea occurred in 29 participants (13.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 0.8 mg LY3502970 Tablet QD" arm (n=213 at risk), Nausea occurred in 7 participants (3.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1B: 1 mg LY3502970 Capsule QD" arm (n=215 at risk), Nausea occurred in 13 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 18)" arm (n=45 at risk), Nausea occurred in 2 participants (4.4%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 17)" arm (n=45 at risk), Nausea occurred in 6 participants (13.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 16)" arm (n=45 at risk), Nausea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 36 mg LY3502970 Capsule QD" arm (n=45 at risk), Nausea occurred in 1 participants (2.2%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 15)" arm (n=50 at risk), Nausea occurred in 4 participants (8.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 14)" arm (n=49 at risk), Nausea occurred in 2 participants (4.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 13)" arm (n=49 at risk), Nausea occurred in 2 participants (4.1%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 24 mg LY3502970 Capsule QD" arm (n=50 at risk), Nausea occurred in 2 participants (4.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 12)" arm (n=50 at risk), Nausea occurred in 4 participants (8.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A:LY3502970 Tablet QD (Dose Level 11)" arm (n=50 at risk), Nausea occurred in 1 participants (2.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: LY3502970 Tablet QD (Dose Level 10)" arm (n=50 at risk), Nausea occurred in 3 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 12 mg LY3502970 Capsule QD" arm (n=50 at risk), Nausea occurred in 3 participants (6.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing)" arm (n=52 at risk), Nausea occurred in 7 participants (13.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 9)" arm (n=46 at risk), Nausea occurred in 5 participants (10.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 8)" arm (n=47 at risk), Nausea occurred in 2 participants (4.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 7)" arm (n=46 at risk), Nausea occurred in 3 participants (6.5%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 6 mg LY3502970 Capsule QD" arm (n=46 at risk), Nausea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 6)" arm (n=51 at risk), Nausea occurred in 2 participants (3.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 5)" arm (n=48 at risk), Nausea occurred in 4 participants (8.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 4)" arm (n=51 at risk), Nausea occurred in 4 participants (7.8%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: 3 mg LY3502970 Capsule QD" arm (n=47 at risk), Nausea occurred in 2 participants (4.3%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 3)" arm (n=52 at risk), Nausea occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 2)" arm (n=52 at risk), Nausea occurred in 1 participants (1.9%). Source: ClinicalTrials.gov results section, adverse events module.

ClinicalTrials.gov results — A Study to Compare Tablets and Capsules of Orforglipron (LY3 — Nausea

Posted trial results for A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight (NCT06440980, PHASE1). In the "Cohort 1A: LY3502970 Tablet QD (Dose Level 1)" arm (n=52 at risk), Nausea occurred in 0 participants (0.0%). Source: ClinicalTrials.gov results section, adverse events module.